GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C6665 Higenamine hydrochlorideSummary: A selective LSD1 inhibitor with anti-inflammatory, anti-apoptotic and osteogenic activities -
C6668 Methylbenactyzine BromideSummary: A selective competitive antagonist of the muscarinic acetylcholine receptor -
C6694 Methacholine chlorideSummary: A diagnostic reagent for measuring airway hyperresponsiveness and assessing asthma -
C6709 Anethole trithioneSummary: A stimulant that promotes bile and saliva secretion for xerostomia -
C6736 Nicotinamide N-oxideSummary: A highly selective CXCR2 receptor antagonist for inflammation -
C6885 Deoxycholic acid sodium saltSummary: An intestinal metabolic byproduct that activates the bile acid receptor TGR5 -
C6974 Trimethobenzamide hydrochlorideSummary: A dopamine D2 receptor blocker for emetic and antiemetic mechanisms -
C7040 Triflupromazine hydrochlorideSummary: A dopamine receptor antagonist for psychiatric disorders -
C7093 Choline bitartrateSummary: An acetylcholine precursor and methyl donor involved in neurotransmission and lipid metabolism -
B8761 MRTX-1133Summary: A selective, non-covalent alkynyl inhibitor targeting the KRAS G12D mutation

